Otelixizumab

Drug Profile

Otelixizumab

Alternative Names: ChAglyCD3; GSK-2136525; Humanised anti-CD3 monoclonal antibody - Tolerx; TRX4

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BTG
  • Developer GlaxoSmithKline; Tolerx
  • Class Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Graves ophthalmopathy; Multiple sclerosis; Myasthenia gravis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 27 Sep 2018 GlaxoSmithKline completes a phase II trial in Type-1 diabetes mellitus in Belgium (IV) (NCT02000817)
  • 24 Jun 2018 Biomarkers information updated
  • 11 Oct 2017 GlaxoSmithKline terminates the phase I TTEDD trial in Type-1 diabetes mellitus in USA and Canada (IV) (NCT00451321)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top